BioAge Labs (BIOA) Receivables (2025 - 2026)
BioAge Labs (BIOA) posted Receivables of $709000.0 for Q1 2026, down 7.8% sequentially from $769000.0 in Q4 2025, and up 96.4% YoY from $361000.0 in Q1 2025.
BioAge Labs (BIOA) Receivables (2025 - 2026) Analysis & Trends
BioAge Labs has reported Receivables for 2 years, with the latest figure at $709000.0 in Q1 2026.
- Quarterly Receivables rose 96.4% year-over-year to $709000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $709000.0 (up 96.4% YoY) and the FY2025 annual result came in at $769000.0, changed N/A from the prior year.
- Receivables retreated to $709000.0 in Q1 2026 per BIOA's latest filing, from $769000.0 in the prior quarter.
- Over five years, Receivables peaked at $769000.0 in Q4 2025 and troughed at $361000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | BioAge Labs | 437.18 Mn | 437.18 Mn | -14.23 Mn | 625,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 625,000.00 |
| Mar 31, 2026 | 709,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Mar 31, 2025 | 361,000.00 |